GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mosaic ImmunoEngineering Inc (OTCPK:CPMV) » Definitions » ROA %

Mosaic ImmunoEngineering (Mosaic ImmunoEngineering) ROA % : -889.58% (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Mosaic ImmunoEngineering ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Mosaic ImmunoEngineering's annualized Net Income for the quarter that ended in Mar. 2024 was $-1.15 Mil. Mosaic ImmunoEngineering's average Total Assets over the quarter that ended in Mar. 2024 was $0.13 Mil. Therefore, Mosaic ImmunoEngineering's annualized ROA % for the quarter that ended in Mar. 2024 was -889.58%.

The historical rank and industry rank for Mosaic ImmunoEngineering's ROA % or its related term are showing as below:

CPMV' s ROA % Range Over the Past 10 Years
Min: -898.49   Med: -36.78   Max: -1.19
Current: -422.32

During the past 13 years, Mosaic ImmunoEngineering's highest ROA % was -1.19%. The lowest was -898.49%. And the median was -36.78%.

CPMV's ROA % is ranked worse than
97.1% of 1551 companies
in the Biotechnology industry
Industry Median: -34.84 vs CPMV: -422.32

Mosaic ImmunoEngineering ROA % Historical Data

The historical data trend for Mosaic ImmunoEngineering's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mosaic ImmunoEngineering ROA % Chart

Mosaic ImmunoEngineering Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 Dec21 Dec22 Dec23
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -35.43 -77.33 -677.21 -898.49 -457.14

Mosaic ImmunoEngineering Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -780.44 30.95 -406.72 -508.15 -889.58

Competitive Comparison of Mosaic ImmunoEngineering's ROA %

For the Biotechnology subindustry, Mosaic ImmunoEngineering's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mosaic ImmunoEngineering's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mosaic ImmunoEngineering's ROA % distribution charts can be found below:

* The bar in red indicates where Mosaic ImmunoEngineering's ROA % falls into.



Mosaic ImmunoEngineering ROA % Calculation

Mosaic ImmunoEngineering's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-1.008/( (0.261+0.18)/ 2 )
=-1.008/0.2205
=-457.14 %

Mosaic ImmunoEngineering's annualized ROA % for the quarter that ended in Mar. 2024 is calculated as:

ROA %=Net Income (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=-1.152/( (0.18+0.079)/ 2 )
=-1.152/0.1295
=-889.58 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data. ROA % is displayed in the 30-year financial page.


Mosaic ImmunoEngineering  (OTCPK:CPMV) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-1.152/0.1295
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-1.152 / 0)*(0 / 0.1295)
=Net Margin %*Asset Turnover
=N/A %*0
=-889.58 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Mosaic ImmunoEngineering ROA % Related Terms

Thank you for viewing the detailed overview of Mosaic ImmunoEngineering's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Mosaic ImmunoEngineering (Mosaic ImmunoEngineering) Business Description

Traded in Other Exchanges
N/A
Address
1537 South Novato Boulevard, Suite 5, Novato, CA, USA, 94947
Mosaic ImmunoEngineering Inc is a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases. The company has a single operating segment for the purposes of assessing performance and making operating decisions.
Executives
Robert Baffi director C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Case Western Reserve University 10 percent owner 10900 EUCLID AVENUE, CLEVELAND OH 44106
Steven W King director, officer: President and CEO
Paul J Lytle director, officer: EVP, Chief Financial Officer
Robert L Garnick director C/O PATRIOT SCIENTIFIC, 2038 CORTE DEL NOGAL, SUITE 141, CARLSBAD CA 92011
Nicole Franziska Steinmetz director, officer: Chief Scientific Officer 871 WILBUR AVENUE, SAN DIEGO CA 92019
Dharmesh Mistry director 315 PEMBROKE COURT, SAN RAMON CA 94582
Carlton M Johnson director
Donald E Schrock director C/O INTEGRATED DEVICE TECHNOLOGY, INC., 6024 SILVER CREEK VALLEY ROAD, SAN JOSE CA 95138
Paul R Bibeau officer: VP, Business Development MICROSEMI CORP, 2381 MORSE AVE, IRVINE CA 92614
Frederick C Goerner officer: Chief Executive Officer MICROSEMI CORPORATION, ONE ENTERPRISE, ALISO VIEJO CA 92656
Clifford L Flowers officer: Chief Financial Officer C/O BAKBONE SOFTWARE, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Harry L Tredennick director 6183 PASEO DEL NORTE #180, CARLSBAD CA 92011
Thomas J Sweeney officer: CFO
Helmut Jr Falk director